Suzhou Fengbei Biotech Stock Co., Ltd. (SHA:603334)
China
· Delayed Price · Currency is CNY 54.89
-0.40 (-0.72%)
Mar 10, 2026, 10:45 AM CST
SHA:603334 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Operating Revenue | 2,810 | 1,945 | 1,726 | 1,704 | 1,292 | 789.15 |
| Other Revenue | 2.82 | 2.82 | 2.07 | 4.44 | 3.11 | 0.66 |
| Revenue | 2,812 | 1,948 | 1,728 | 1,709 | 1,296 | 789.81 |
| Revenue Growth (YoY) | 62.77% | 12.75% | 1.12% | 31.89% | 64.04% | - |
| Cost of Revenue | 2,550 | 1,721 | 1,489 | 1,478 | 1,101 | 675.55 |
| Gross Profit | 261.91 | 226.71 | 238.43 | 230.89 | 195.08 | 114.26 |
| Selling, General & Admin | 53.11 | 50.88 | 56.84 | 41.13 | 36.24 | 23.98 |
| Research & Development | 67.48 | 53.57 | 58.57 | 51.35 | 41.88 | 25.25 |
| Other Operating Expenses | -23.45 | -8.24 | -16.7 | -6.63 | -5.9 | 1.19 |
| Operating Expenses | 101.07 | 100.76 | 95.55 | 87.74 | 73.79 | 51.74 |
| Operating Income | 160.84 | 125.95 | 142.89 | 143.15 | 121.29 | 62.52 |
| Interest Expense | -6.22 | -6 | -7.12 | -6.28 | -3.35 | -4.53 |
| Interest & Investment Income | 0.42 | 1.01 | 2.93 | 0.63 | 2.31 | 0.06 |
| Currency Exchange Gain (Loss) | 4.65 | 4.65 | 2.71 | 9.87 | - | - |
| Other Non Operating Income (Expenses) | -4.11 | -0.92 | -4.7 | -0.68 | -3.05 | -2.94 |
| EBT Excluding Unusual Items | 155.57 | 124.69 | 136.72 | 146.69 | 117.19 | 55.11 |
| Gain (Loss) on Sale of Investments | -0.5 | -0.34 | -4.02 | -5.03 | -0.72 | 0.44 |
| Gain (Loss) on Sale of Assets | 0.05 | 0.05 | 0.02 | -0.06 | -0.41 | - |
| Asset Writedown | -0.17 | -0.06 | -0.76 | -1.7 | -0.54 | -0.52 |
| Legal Settlements | - | - | - | - | -1 | - |
| Other Unusual Items | 10.09 | 10.09 | 12.45 | 3.58 | -6.1 | 3.64 |
| Pretax Income | 165.03 | 134.42 | 144.41 | 143.47 | 108.42 | 58.67 |
| Income Tax Expense | 10.59 | 10.6 | 14.7 | 10.12 | 6.38 | 8.98 |
| Earnings From Continuing Operations | 154.44 | 123.82 | 129.71 | 133.35 | 102.03 | 49.69 |
| Minority Interest in Earnings | - | - | - | -0 | -0.12 | -0.69 |
| Net Income | 154.44 | 123.82 | 129.71 | 133.35 | 101.91 | 49 |
| Net Income to Common | 154.44 | 123.82 | 129.71 | 133.35 | 101.91 | 49 |
| Net Income Growth | 19.06% | -4.54% | -2.73% | 30.85% | 107.98% | - |
| Shares Outstanding (Basic) | 108 | 108 | 107 | 106 | 106 | 100 |
| Shares Outstanding (Diluted) | 108 | 108 | 107 | 106 | 106 | 100 |
| Shares Change (YoY) | 0.86% | 0.44% | 1.29% | -0.31% | 6.16% | - |
| EPS (Basic) | 1.43 | 1.15 | 1.21 | 1.26 | 0.96 | 0.49 |
| EPS (Diluted) | 1.43 | 1.15 | 1.21 | 1.26 | 0.96 | 0.49 |
| EPS Growth | 18.05% | -4.96% | -3.97% | 31.25% | 95.92% | - |
| Free Cash Flow | -78.61 | -57.1 | -5.62 | -10.38 | 5.01 | 58.84 |
| Free Cash Flow Per Share | -0.73 | -0.53 | -0.05 | -0.10 | 0.05 | 0.59 |
| Gross Margin | 9.31% | 11.64% | 13.80% | 13.51% | 15.06% | 14.47% |
| Operating Margin | 5.72% | 6.46% | 8.27% | 8.38% | 9.36% | 7.92% |
| Profit Margin | 5.49% | 6.36% | 7.51% | 7.80% | 7.87% | 6.20% |
| Free Cash Flow Margin | -2.79% | -2.93% | -0.33% | -0.61% | 0.39% | 7.45% |
| EBITDA | 182.31 | 142.16 | 155.76 | 154.31 | 131.2 | 69.8 |
| EBITDA Margin | 6.48% | 7.30% | 9.01% | 9.03% | 10.13% | 8.84% |
| D&A For EBITDA | 21.47 | 16.21 | 12.87 | 11.16 | 9.91 | 7.27 |
| EBIT | 160.84 | 125.95 | 142.89 | 143.15 | 121.29 | 62.52 |
| EBIT Margin | 5.72% | 6.46% | 8.27% | 8.38% | 9.36% | 7.92% |
| Effective Tax Rate | 6.42% | 7.89% | 10.18% | 7.05% | 5.89% | 15.31% |
| Revenue as Reported | 2,812 | 1,948 | 1,728 | 1,709 | - | - |
| Advertising Expenses | - | 0.43 | 0.46 | 0.2 | 0.16 | 0.1 |
Source: S&P Capital IQ. Standard template. Financial Sources.